PHVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pharvaris N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Apr 2, 2026
$29.77+2.03 (+7.32%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2023 Ended Jun 30, 2023 | Aug 7, 2023 | Before market open | – | $0.63 | – |
| Q2 FY2022 Ended Jun 30, 2022 | Sep 12, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 29, 2022 | Before market open | – | – | – |
Press releases
Announcements Pharvaris filed with the SEC
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.3 to Form 6-K
Pharvaris Announces Annual General Meeting of Shareholders
EX-99.1 to Form 6-K
The agenda for the AGM is as follows:
EX-99.2 to Form 6-K
acting on behalf of (only to be completed if relevant)
EX-99.3 to Form 6-K
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.3 to Form 6-K
Pharvaris Outlines 2026 Strategic Priorities
EX-99.1 to Form 6-K
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal
EX-99.1 to Form 6-K
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.3 to Form 6-K
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.3 to Form 6-K
Pharvaris Updates Timing of Topline Data Announcement for
EX-99.1 to Form 6-K
Pharvaris Announces Annual Meeting of Shareholders
EX-99.1 to Form 6-K
The agenda for the AGM is as follows:
EX-99.2 to Form 6-K
acting on behalf of (only to be completed if relevant)
EX-99.3 to Form 6-K
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.3 to Form 6-K
Pharvaris Outlines 2025 Strategic Priorities
EX-99.1 to Form 6-K
Unaudited Condensed Consolidated Interim Financial Statements
EX-99.3 to Form 6-K
AnalytiCon Discovery GmbH and Pharvaris NV on 31 st March 2016,
EX-99.1 to Form 6-K
Pharvaris Presents Data at the Bradykinin Symposium 2024
EX-99.1 to Form 6-K